现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2015年
9期
1283-1286
,共4页
受体,表皮生长因子%前列腺素内过氧化物合酶类%抗肿瘤药%结肠肿瘤%细胞增殖%细胞抑制剂
受體,錶皮生長因子%前列腺素內過氧化物閤酶類%抗腫瘤藥%結腸腫瘤%細胞增殖%細胞抑製劑
수체,표피생장인자%전렬선소내과양화물합매류%항종류약%결장종류%세포증식%세포억제제
Receptor,epidermal growth factor%Prostaglandin-endoperoxide synthases%Antineoplastic agents%Colonic neoplasms%Cell proliferation%Cytostatic agents
目的：探讨表皮生长因子受体（EGFR）抑制剂及环氧化酶-2（COX-2）抑制剂埃罗替尼、塞来昔布及二者联合用药对结肠癌细胞HT-29增殖的抑制作用及其机制。方法将HT-29细胞分为对照组（完全培养基）、塞来昔布组（220μmol/L）、埃罗替尼组（50μmol/L）及联合用药组（塞来昔布220μmol/L、埃罗替尼50μmol/L）四组，作相应处理后均在适宜条件下培养；48 h后采用MTT法观察细胞抑制率，Real-time PCR法及Western blotting法检测EGFR、COX-2 mRNA及蛋白表达情况，ELISA法检测前列腺素E2（PGE2）含量。结果48 h后塞来昔布组和埃罗替尼组对HT-29细胞抑制率分别为（56.6±4.3）％和（56.9±3.9）％，联合用药组抑制率为（86.1±7.1）％，与单独用药组比较，联合用药组对HT-29细胞增殖的抑制作用更明显，差异有统计学意义（P<0.05或0.01）；与对照组比较，埃罗替尼组、塞来昔布组均能降低HT-29细胞中COX-2及EGFR的mRNA及蛋白表达水平，也可降低HT-29细胞PGE2的分泌，且联合用药组效果较单一用药组更显著，差异均有统计学意义（P<0.01）。结论塞来昔布和埃罗替尼均能抑制结肠肿瘤的细胞生长，可同时阻断EGFR、COX-2信号通路，二者联合应用具有协同作用，其机制可能是抑制EGFR、COX-2的表达及PGE2的分泌。
目的：探討錶皮生長因子受體（EGFR）抑製劑及環氧化酶-2（COX-2）抑製劑埃囉替尼、塞來昔佈及二者聯閤用藥對結腸癌細胞HT-29增殖的抑製作用及其機製。方法將HT-29細胞分為對照組（完全培養基）、塞來昔佈組（220μmol/L）、埃囉替尼組（50μmol/L）及聯閤用藥組（塞來昔佈220μmol/L、埃囉替尼50μmol/L）四組，作相應處理後均在適宜條件下培養；48 h後採用MTT法觀察細胞抑製率，Real-time PCR法及Western blotting法檢測EGFR、COX-2 mRNA及蛋白錶達情況，ELISA法檢測前列腺素E2（PGE2）含量。結果48 h後塞來昔佈組和埃囉替尼組對HT-29細胞抑製率分彆為（56.6±4.3）％和（56.9±3.9）％，聯閤用藥組抑製率為（86.1±7.1）％，與單獨用藥組比較，聯閤用藥組對HT-29細胞增殖的抑製作用更明顯，差異有統計學意義（P<0.05或0.01）；與對照組比較，埃囉替尼組、塞來昔佈組均能降低HT-29細胞中COX-2及EGFR的mRNA及蛋白錶達水平，也可降低HT-29細胞PGE2的分泌，且聯閤用藥組效果較單一用藥組更顯著，差異均有統計學意義（P<0.01）。結論塞來昔佈和埃囉替尼均能抑製結腸腫瘤的細胞生長，可同時阻斷EGFR、COX-2信號通路，二者聯閤應用具有協同作用，其機製可能是抑製EGFR、COX-2的錶達及PGE2的分泌。
목적：탐토표피생장인자수체（EGFR）억제제급배양화매-2（COX-2）억제제애라체니、새래석포급이자연합용약대결장암세포HT-29증식적억제작용급기궤제。방법장HT-29세포분위대조조（완전배양기）、새래석포조（220μmol/L）、애라체니조（50μmol/L）급연합용약조（새래석포220μmol/L、애라체니50μmol/L）사조，작상응처리후균재괄의조건하배양；48 h후채용MTT법관찰세포억제솔，Real-time PCR법급Western blotting법검측EGFR、COX-2 mRNA급단백표체정황，ELISA법검측전렬선소E2（PGE2）함량。결과48 h후새래석포조화애라체니조대HT-29세포억제솔분별위（56.6±4.3）％화（56.9±3.9）％，연합용약조억제솔위（86.1±7.1）％，여단독용약조비교，연합용약조대HT-29세포증식적억제작용경명현，차이유통계학의의（P<0.05혹0.01）；여대조조비교，애라체니조、새래석포조균능강저HT-29세포중COX-2급EGFR적mRNA급단백표체수평，야가강저HT-29세포PGE2적분비，차연합용약조효과교단일용약조경현저，차이균유통계학의의（P<0.01）。결론새래석포화애라체니균능억제결장종류적세포생장，가동시조단EGFR、COX-2신호통로，이자연합응용구유협동작용，기궤제가능시억제EGFR、COX-2적표체급PGE2적분비。
Objective To investigate the synergistic inhibitory effect of EGFR and COX-2 inhibitors named celecoxib and erlotinib or its combinations on the proliferation of colorectal cancer cell lines HT-29 and its possible mechanism. Methods The HT-29 cells were divided into four groups such as the control group (complete medium),the celecoxib group (220μmol/L), the erlotinib group(50μmol/L) and the combination group(220μmol/L celecoxib,50μmol/L erlotinib) according to different medications,all of which were cultivated under appropriate environments. It adopted MTT assay to observe the cell inhibitory rate,Real-time PCR and Western blotting assays to detect the expressions of EGFR,COX-2mRNA and proteinand ELISA assay to measure the content of PGE2 after 48 hours. Results The inhibition rates on HT-29 cells in the celecoxib group and the erlotinib group after 48 hours were(56.6±4.3)%and(56.9±3.9)%respectively while the combination group being(86.1±7.1)%,the prolifer-ation of HT-29 cell was inhibited in the combination group more apparently than in the celecoxib group and erlotinib group ,which had statistically significant difference(P<0.05 or 0.01);compared with the control group,both the celecoxib group and the erlotinib group were reduced COX-2 in the HT-29,mRNA of EGFR and expression level of protein,as well as PGE2 secretion of HT-29 cells. The combination group was more significant than the single group in effect , all of which had statistical significance in dif ference(P<0.01). Conclusions Celecoxib and erlotinib may depress the growth of colorectal cancer cell lines,block the communi-cation paths of EGFR and COX-2 simultaneously,both of which have a synergistic inhibitory effect,whose possible mechanism may be inhibit expression of EGFR,COX-2 and secretion of PGE2.
